drugset
drugset / Trial / NCT03001544

Study of Safety and Biomarker Efficacy of TS23 in Healthy Volunteer

NCT03001544 ↗

Phase 1 Unknown 24 enrolled Translational Sciences, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This study is designed to determine the safety, pharmacokinetics and pharmacodynamics of a single intravenous dose of TS23 in healthy adults.

Timeline

Start
2015-07
Primary completion
2016-06
Completion
2017-06

Drugs

EvaluationDrugModalityDoseRoute
Subject TS23 Monoclonal antibody — Intravenous

Indications

brain ischemia myocardial infarction pulmonary embolism thrombotic disease venous thromboembolism